Ordering
  • Test code: 73000
  • Turnaround time:
    4 calendar days
  • Preferred specimen:
    3mL whole blood in a purple-top tube
  • Alternate specimens:
    Saliva and assisted saliva are accepted; DNA is not accepted
  • Sample requirements
  • Request a sample kit
Billing
 

Invitae Spinal Muscular Atrophy STAT Panel

Test description

The Invitae Spinal Muscular Atrophy STAT test analyzes the copy number of SMN1, which is known to cause spinal muscular atrophy (SMA), and SMN2, which can modify the phenotype in individuals with SMN1-related SMA. This test does not detect SMN1 sequence variants.

This test provides an accelerated 4 day turnaround time (TAT), which can facilitate urgent management and treatment decisions. Identification of homozygous deletion of SMN1 combined with determination of SMN2 copy number is a predictor of disease severity and identifies those that would benefit from new and emerging therapies. Early intervention is critical to modulate the progressive degeneration seen in SMA.

Order test

Primary panel (2 genes)

Alternative tests to consider

This test analyzes SMN1 and SMN2 copy number but does not detect SMN1 sequence variants, which are found in 2-5% of individuals affected with SMA. If there is reason to suspect a patient carries a sequence variant, the Invitae Spinal Muscular Atrophy Panel should be considered instead:




SMN1 and SMN2 can also be ordered as a part of a broader panel. Depending on the individual’s clinical and family history, one of these broader panels may be appropriate:




Please note that re-requisitions to other neuromuscular panels is not available for SMA STAT panel orders. Any additional test requisitions will require an additional sample and billing event.

Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by the loss of motor neurons within the spinal cord, which results in progressive muscle weakness and atrophy. Other features of SMA may include muscle fasciculations, tremors, poor weight gain, sleeping difficulties, pneumonia, scoliosis, joint contractures, and congenital heart disease. Four clinical SMA subtypes have been distinguished: severe infantile acute SMA type I (also referred to as Werdnig-Hoffman disease), infantile chronic SMA type II, juvenile SMA type III (also referred to as Wohlfard-Kugelberg-Welander disease), and adult-onset SMA type IV.

Type I infants are hypotonic and have severe proximal muscle wasting due to a loss of motor neurons in the anterior horn of the spinal cord. These individuals are diagnosed prenatally or within 6 months after birth. They never sit unaided and usually succumb to the disease within the first 2 years, most often due to respiratory muscle weakness. Individuals with intermediate SMA type II develop the disease before 18 months of age, are able to sit unaided, but do not stand or walk. Individuals with SMA type III are diagnosed after 18 months, are able to walk and often live at least into the second or third decade. Individuals with SMA Type IV walk during adult years and are typically diagnosed in the second or third decade. The age of onset, phenotype, prognosis, and life expectancy display marked inter- and intrafamilial variability.

Approximately 95%-98% of individuals with SMA are homozygous for a deletion or gene conversion of SMN1 to SMN2 and about 2%-5% are compound heterozygotes for an SMN1 deletion or conversion mutation and an SMN1 pathogenic sequence variant. This test analyzes SMN1 and SMN2 copy number but does not detect sequence variants and has a reduced clinical sensitivity compared to the Invitae Spinal Muscular Atrophy Panel.

SMA is inherited in an autosomal recessive manner. Up to 2% of pathogenic SMN1 alleles occur de novo. Some heterozygous carriers (an estimated 8% of Ashkenazi Jewish carriers) appear to have normal SMN1 genetic testing results due to two functional copies of SMN1 on one chromosome and a deletion on the other chromosome, a situation referred to as “silent carrier”. This assay does not detect silent carriers.

On its own, homozygous deletion of SMN1 has high penetrance. However, penetrance is complicated by modifying effects of SMN2 copy number. Unaffected individuals with five copies of SMN2 and a homozygous deletion in SMN1 have been reported, suggesting that five copies of SMN2 may compensate for the lack of SMN1 expression (PMID: 15378550).

The prevalence of SMA I, II and III is estimated to be <2 per 100,000 in the general population, and the incidence of severe infantile acute SMA type I is estimated to be 4-10 individuals per 100,000 live births.

Genetic testing may confirm a suspected diagnosis or rule out disorders with similar symptoms. A genetic diagnosis may also help predict disease progression, inform recurrence risk, and guide treatment and enrollment in clinical trials.

  1. Prior, TW, Russman, BS. Spinal Muscular Atrophy. 2000 Feb 24. In: Pagon, RA, et al, editors. GeneReviews(®) (Internet). University of Washington, Seattle. PMID: 20301526
  2. Kolb, SJ, Kissel, JT. Spinal Muscular Atrophy. Neurol Clin. 2015; 33(4):831-46. PMID: 26515624
  3. Wang, CH, et al. Consensus statement for standard of care in spinal muscular atrophy. J. Child Neurol. 2007; 22(8):1027-49. PMID: 17761659
  4. Prior, TW, et al. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am. J. Med. Genet. A. 2004; 130A(3):307-10. PMID: 15378550
  5. Wirth, B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. 2000; 15(3):228-37. PMID: 10679938
  6. Lunn, MR, Wang, CH. Spinal muscular atrophy. Lancet. 2008; 371(9630):2120-33. PMID: 18572081
  7. Brahe, C, et al. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. Lancet. 1995; 346(8977):741-2. PMID: 7658877
  8. Mailman, MD, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med. 2002; 4(1):20-6. PMID: 11839954
  9. Wirth, B, et al. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am. J. Hum. Genet. 1997; 61(5):1102-11. PMID: 9345102
  10. Pearn, J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 1978; 15(6):409-13. PMID: 745211
  11. Lin, CW. Kalb, SJ. Yeh, WS. Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review. Pediatr Neurol. 2015 Oct;53(4):293-300. doi: 10.1016/j.pediatrneurol.2015.06.002. Epub 2015 Jun 10. PMID: 26260993

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
SMN1, SMN2* SMN1: NM_000344.3, SMN2: NM_017411.3

SMN1, SMN2: The SMN1 gene is identical to the SMN2 gene with the exception of exon 8 (also known as exon 7). This assay unambiguously detects SMN1 and SMN2 exon 8 copy number, which is used to infer the copy number of the entire SMN1 and SMN2 gene, respectively. SMN2 exon 8 copy number is only reported for individuals with a homozygous deletion of SMN1 exon 8. This test does not detect sequence variants in SMN1 or SMN2, and therefore cannot be used to identify compound heterozygotes. This test also does not detect silent carriers (individuals that have 2 functional copies of SMN1 on one chromosome and zero copies on the other). Therefore a negative result for carrier testing greatly reduces but does not eliminate the chance that a person is a carrier. For individuals with 2 copies of SMN1, the residual risk of being a carrier has been reported to be 1 in 121 in African Americans, 1 in 345 in Ashkenazi Jewish individuals, 1 in 628 in Asians, 1 in 632 in Caucasians, and 1 in 1061 in Hispanic individuals (PMID: 23788250).